HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors.

加利福尼亚州亨廷顿海滩（商业新闻短讯）--开发全人工心脏（TAH）的临床阶段医疗技术公司BiVACOR，Inc.今天宣布，雷蒙德·科恩（RaymondW.Cohen）被任命为董事会主席。

Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018.

科恩先生是经认可的上市公司董事，在生命科学行业拥有40多年的经验。他目前担任Axonics，Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics，Inc是一家总部位于加利福尼亚州欧文市的全球医疗技术公司，于2013年共同成立，并于2018年10月上市。

Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas..

Axonics在2021年德勤科技快速500强中排名第一™ 以及2022年《金融时报》对美洲500家增长最快公司的排名。。

Mr. Cohen also serves as an independent director of SoniVie Ltd., a clinical-stage venture backed company developing a denervation technology for uncontrolled hypertension. In late 2020, Mr. Cohen was named as Entrepreneur of the Year by Ernst & Young for the Pacific Southwest United States.

科恩先生还担任SoniVie Ltd.的独立董事，SoniVie Ltd.是一家临床阶段风险投资支持的公司，正在开发一种针对不受控制的高血压的去神经技术。2020年末，科恩先生被安永会计师事务所评为美国西南太平洋地区的年度企业家。

In late November, BiVACOR announced that the U.S. Food and Drug Administration approved an investigational device exemption allowing the company to conduct a first-in-human clinical feasibility study of the BiVACOR TAH. The study will evaluate the safety and feasibility of the TAH as a bridge to heart transplant in the treatment of subjects with biventricular heart failure.

11月下旬，BiVACOR宣布，美国食品和药物管理局批准了一项研究设备豁免，允许该公司对BiVACOR TAH进行首次人体临床可行性研究。该研究将评估TAH作为心脏移植治疗双心室心力衰竭患者的桥梁的安全性和可行性。

Initially three patients will be enrolled at The Texas Heart Institute in Houston. The study is anticipated to commence in the first half of 2024..

最初，休斯顿德克萨斯心脏研究所将招募三名患者。预计该研究将于2024年上半年开始。。

“A total artificial heart is designed to take over the complete function of a patient’s failing heart and represents an advanced treatment option for people waiting on a heart transplant or those who do not qualify for certain reasons,” said Mr. Cohen. “The work done by BiVACOR over the past 15 years to develop the TAH system is impressive.

科恩先生说：“全人工心脏旨在接管患者衰竭心脏的全部功能，对于等待心脏移植的人或因某些原因不符合条件的人来说，它是一种先进的治疗选择。”。“BiVACOR在过去15年中为开发TAH系统所做的工作令人印象深刻。

I’ve spent much of my career in cardiology and consider it a privilege to join Dr. Timms and Dr. Cohn on this amazing journey.”.

我在心脏病学领域度过了职业生涯的大部分时间，我很荣幸能与蒂姆斯博士和科恩博士一起踏上这段神奇的旅程。”。

According to the U.S. National Institutes of Health, approximately 100,000 patients suffering from severe heart failure could benefit from BiVACOR’s unique TAH. For these patients, drug therapy is limited and without intervention, they have a bleak outlook given the low number of donor hearts available globally..

根据美国国立卫生研究院（National Institutes of Health）的数据，比瓦科（BiVACOR）独特的TAH可以使大约100000名患有严重心力衰竭的患者受益。对于这些患者来说，药物治疗是有限的，如果不进行干预，鉴于全球可用的供体心脏数量很少，他们的前景黯淡。。

About BiVACOR®

关于BiVACOR®

BiVACOR is a clinical-stage medical technology company developing the BiVACOR Total Artificial Heart, designed to be the first long-term therapy for patients with severe biventricular heart failure. The TAH is designed to replace the naive heart and address the global unmet need of patients with end-stage heart failure by providing a next-generation life-extending solution.

BiVACOR是一家临床阶段的医疗技术公司，开发BiVACOR全人工心脏，旨在成为严重双心室心力衰竭患者的首个长期治疗方法。TAH旨在替代幼稚的心脏，并通过提供下一代延长寿命的解决方案来解决终末期心力衰竭患者的全球未满足需求。

BiVACOR was founded in 2008 by a team of internationally renowned biomedical engineers and cardiac surgeons, including founder and chief technical officer Daniel Timms, Ph.D., and chief medical officer William Cohn, M.D..

BiVACOR成立于2008年，由国际知名的生物医学工程师和心脏外科医生组成，其中包括创始人兼首席技术官Daniel Timms博士和首席医疗官William Cohn博士。。

Learn more about BiVACOR by visiting https://bivacor.com

通过访问了解有关BiVACOR的更多信息https://bivacor.com